Inhibrx Inc (INBX)
34.15
+0.14
(+0.41%)
USD |
NASDAQ |
May 03, 16:00
34.16
+0.01
(+0.03%)
After-Hours: 20:00
Inhibrx Research and Development Expense (TTM): 191.64M for Dec. 31, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 191.64M |
| September 30, 2023 | 140.00M |
| June 30, 2023 | 126.88M |
| March 31, 2023 | 122.68M |
| December 31, 2022 | 110.19M |
| September 30, 2022 | 98.35M |
| June 30, 2022 | 91.90M |
| March 31, 2022 | 79.90M |
| December 31, 2021 | 71.44M |
| September 30, 2021 | 70.49M |
| Date | Value |
|---|---|
| June 30, 2021 | 71.84M |
| March 31, 2021 | 72.92M |
| December 31, 2020 | 73.50M |
| September 30, 2020 | 68.11M |
| June 30, 2020 | 61.06M |
| March 31, 2020 | 54.26M |
| December 31, 2019 | 47.91M |
| September 30, 2019 | 44.12M |
| June 30, 2019 | 42.11M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
42.11M
Minimum
Jun 2019
191.64M
Maximum
Dec 2023
86.28M
Average
72.92M
Median
Mar 2021
Research and Development Expense (TTM) Benchmarks
| Axonics Inc | 37.89M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.80M |
| iBio Inc | 8.141M |
| Theriva Biologics Inc | 14.31M |